AAPS PharmSci 360 2026:USP 专家谈 E&L 分析系统适用性标准化与 4 种混合物
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
USP 正推动提取物与浸出物(E&L)分析的系统适用性标准化,并已通过跨实验室国际比对研究形成 4 种覆盖有机 E&L 筛查主要技术的系统适用性混合物。
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
Ravi Kiran Kaja, PhD, senior principal Scientist at the United States Pharmacopeia (USP), spoke with PharmTech ahead of AAPS PharmSci 360, which is taking place October 25-28, 2026 in New Orleans, about USP’s work to standardize system suitability testing for extractables and leachables (E&L) analysis. Kaja leads USP initiatives on complex drug products, pharmaceutical packaging, drug-device combination products and E&L standards. He also represents USP on the International Council for Harmonisation’s Q3E Expert Working Group and serves on the AAPS PharmSci 360 Scientific Programming Committee.
Kaja explains that system suitability standards are a quality check on the analytical system before a laboratory starts an E&L study. E&L testing looks for trace-level unknown compounds across a broad chemical space using techniques such as gas chromatography-mass spectroscopy (GC-MS) and liquid chromatography-MS. Because of this, small differences in instrument performance, sensitivity, or chromatographic separation can significantly change results. Until now there has been no standardized way to evaluate system performance in E&L screening, so 2 laboratories analyzing the same sample could reach different conclusions. A common framework for checking performance makes the data more trustworthy and easier to compare between laboratories. It also strengthens the patient safety decisions that rely on those data. As Kaja puts it, data cannot be compared until the quality of the measurement system producing them is standardized.
To close this gap, USP launched a global initiative with industry, regulators, manufacturers, and contract laboratories. The effort began with stakeholder engagement and scientific publications and grew into a large international round-robin study across multiple laboratories and analytical platforms. From those results, USP developed and refined 4 system suitability mixtures covering the major techniques used in organic E&L screening. Kaja stresses that the initiative is built on real-world laboratory experience and broad participation rather than on a single laboratory’s approach. Next, USP plans to encourage wider adoption, gather more implementation data, and fold what it learns into the modernization of its E&L standards framework. The aim is to build confidence in the data those standards produce.
Related to this article
来源:PharmTech Quality Systems · pharmtech.com